Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Hereditary breast cancer: the era of new susceptibility genes.

Apostolou P, Fostira F.

Biomed Res Int. 2013;2013:747318. doi: 10.1155/2013/747318. Epub 2013 Mar 21. Review.

2.

Translational advances regarding hereditary breast cancer syndromes.

Gage M, Wattendorf D, Henry LR.

J Surg Oncol. 2012 Apr 1;105(5):444-51. doi: 10.1002/jso.21856. Review.

PMID:
22441895
3.

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC.

JAMA. 2006 Mar 22;295(12):1379-88.

PMID:
16551709
4.

Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.

Blanco A, Graña B, Fachal L, Santamariña M, Cameselle-Teijeiro J, Ruíz-Ponte C, Carracedo A, Vega A.

Clin Genet. 2010 Feb;77(2):193-6. doi: 10.1111/j.1399-0004.2009.01309.x. Epub 2009 Nov 23. No abstract available.

PMID:
19930417
5.

Ten genes for inherited breast cancer.

Walsh T, King MC.

Cancer Cell. 2007 Feb;11(2):103-5.

6.

Breast cancer predisposition syndromes.

Hemel D, Domchek SM.

Hematol Oncol Clin North Am. 2010 Oct;24(5):799-814. doi: 10.1016/j.hoc.2010.06.004. Review.

PMID:
20816575
7.

Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.

Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH.

Breast Cancer Res. 2012 Apr 16;14(2):R66.

8.

Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.

Konecny M, Milly M, Zavodna K, Weismanova E, Gregorova J, Mlkva I, Ilencikova D, Kausitz J, Bartosova Z.

Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.

PMID:
21203900
9.

Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.

Guénard F, Pedneault CS, Ouellette G, Labrie Y, Simard J; INHERIT, Durocher F.

Genet Test Mol Biomarkers. 2010 Aug;14(4):515-26. doi: 10.1089/gtmb.2010.0027.

PMID:
20722467
10.

Pathology of hereditary breast cancer.

van der Groep P, van der Wall E, van Diest PJ.

Cell Oncol (Dordr). 2011 Apr;34(2):71-88. doi: 10.1007/s13402-011-0010-3. Epub 2011 Feb 19. Review.

11.

Beyond BRCA: new hereditary breast cancer susceptibility genes.

Economopoulou P, Dimitriadis G, Psyrri A.

Cancer Treat Rev. 2015 Jan;41(1):1-8. doi: 10.1016/j.ctrv.2014.10.008. Epub 2014 Nov 6. Review.

PMID:
25467110
12.

Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management.

Kleibl Z, Kristensen VN.

Breast. 2016 Aug;28:136-44. doi: 10.1016/j.breast.2016.05.006. Epub 2016 Jun 16. Review.

PMID:
27318168
13.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

14.

Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families.

Guénard F, Labrie Y, Ouellette G, Beauparlant CJ, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Durocher F; INHERIT BRCAs.

Fam Cancer. 2007;6(4):483-90. Epub 2007 Jul 17.

PMID:
17636424
15.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.

Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.

Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.

PMID:
21562711
16.

Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.

Johnson N, Fletcher O, Palles C, Rudd M, Webb E, Sellick G, dos Santos Silva I, McCormack V, Gibson L, Fraser A, Leonard A, Gilham C, Tavtigian SV, Ashworth A, Houlston R, Peto J.

Hum Mol Genet. 2007 May 1;16(9):1051-7. Epub 2007 Mar 6.

PMID:
17341484
17.

Germline TP53 mutational spectrum in French Canadians with breast cancer.

Arcand SL, Akbari MR, Mes-Masson AM, Provencher D, Foulkes WD, Narod SA, Tonin PN.

BMC Med Genet. 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y.

18.

Inherited mutations in breast cancer genes--risk and response.

Shuen AY, Foulkes WD.

J Mammary Gland Biol Neoplasia. 2011 Apr;16(1):3-15. doi: 10.1007/s10911-011-9213-5. Epub 2011 Apr 5. Review.

PMID:
21461995
19.

Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population.

Cao AY, Jin W, Shi PC, Di GH, Shen ZZ, Shao ZM.

Breast Cancer Res Treat. 2010 Jan;119(2):295-303. doi: 10.1007/s10549-009-0349-6. Epub 2009 Feb 24.

PMID:
19238535
20.

Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.

Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T; kConFab Investigators, Fellowes A, Dobrovic A, Fox SB.

Br J Cancer. 2014 Dec 9;111(12):2351-60. doi: 10.1038/bjc.2014.511.

Supplemental Content

Support Center